DNA & Genetics Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero AcquisitionBy adminOctober 14, 20250 If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B)…
